127 related articles for article (PubMed ID: 38355375)
1. Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.
Subiela JD; Krajewski W; González-Padilla DA; Laszkiewicz J; Taborda J; Aumatell J; Sanchez Encinas M; Basile G; Moschini M; Caño-Velasco J; Lopez Perez E; Del Olmo Durán P; Gallioli A; Tukiendorf A; D'Andrea D; Yuen-Chun Teoh J; Serna Céspedes A; Pichler R; Afferi L; Del Giudice F; Gomez Rivas J; Albisinni S; Soria F; Ploussard G; Mertens LS; Rajwa P; Laukhtina E; Pradere B; Tully K; Guerrero-Ramos F; Rodríguez-Faba Ó; Alvarez-Maestro M; Dominguez-Escrig JL; Szydełko T; Gomez Dos Santos V; Jiménez Cidre MÁ; Burgos Revilla FJ;
Eur Urol Oncol; 2024 Feb; ():. PubMed ID: 38355375
[TBL] [Abstract][Full Text] [Related]
2. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy.
Contieri R; Hensley PJ; Tan WS; Grajales V; Bree K; Nogueras-Gonzalez GM; Lee BH; Navai N; Dinney CP; Kamat AM
Eur Urol Oncol; 2023 Dec; 6(6):590-596. PubMed ID: 37558542
[TBL] [Abstract][Full Text] [Related]
3. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.
Lobo N; Hensley PJ; Bree KK; Nogueras-Gonzalez GM; Navai N; Dinney CP; Sylvester RJ; Kamat AM
Eur Urol Oncol; 2022 Feb; 5(1):84-91. PubMed ID: 34920986
[TBL] [Abstract][Full Text] [Related]
4. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
5. Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guérin: Implications for Risk-adapted Follow-up.
Subiela JD; Rodríguez Faba Ó; Aumatell J; Gonzalez-Padilla DA; Rosales Bordes A; Huguet J; Krajewski W; Algaba F; López Curtis D; Brasero Burgos J; Sánchez González Á; Jiménez Cidre MÁ; Burgos Revilla FJ; Breda A; Palou J
Eur Urol Focus; 2023 Mar; 9(2):325-332. PubMed ID: 36163105
[TBL] [Abstract][Full Text] [Related]
6. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes.
Tan WS; Grajales V; Contieri R; Hensley P; Bree K; Msaouel P; Guo CC; Nogueras-Gonzalez GM; Navai N; Dinney CP; Kamat AM
Eur Urol Open Sci; 2023 Jul; 53():16-22. PubMed ID: 37441349
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer.
Tan X; Liu Z; Cai T; Wang Y; Wu Z; Qin Z; Li Z; Liu Z; Yuan G; Zhou Q; Yao K
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37884420
[TBL] [Abstract][Full Text] [Related]
9. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
10. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
[TBL] [Abstract][Full Text] [Related]
11. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
12. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
[TBL] [Abstract][Full Text] [Related]
13. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapy.
Piszczek R; Krajewski W; Subiela JD; Del Giudice F; Nowak Ł; Chorbińska J; Moschini M; Masson-Lecomte A; Bebane S; Cimadamore A; Grobet-Jeandin E; Rouprêt M; D'Andrea D; Mastroianni R; Gutierrez Hidalgo B; Gomez Rivas J; Mori K; Soria F; Laukhtina E; Mari A; Albisinni S; Gallioli A; Mertens LS; Pichler R; Marcq G; Łaszkiewicz J; Hałoń A; Carrion DM; Akand M; Pradere B; Shariat SF; Palou J; Babjuk M; Burgos Revilla J; Małkiewicz B; Szydełko T;
Minerva Urol Nephrol; 2023 Oct; 75(5):591-599. PubMed ID: 37728495
[TBL] [Abstract][Full Text] [Related]
15. [Intravesical instillation of bacillus Calmette-Guerin for non-muscle invasive bladder cancer: outcomes of 421 patients in a single center].
Cai T; Lu J; Lin Z; Lup M; Liang H; Qin Z; Ye Y
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Mar; 43(3):488-494. PubMed ID: 37087596
[TBL] [Abstract][Full Text] [Related]
16. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
18. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the oncological outcomes of three different bacillus Calmette-Guérin strains in patients with high-grade T1 non-muscle-invasive bladder cancer.
Nowak Ł; Krajewski W; Moschini M; Chorbińska J; Poletajew S; Tukiendorf A; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Orlando R; Di Trapani E; Alvarez-Maestro M; Simone G; Zamboni S; Simeone C; Marconi MC; Mastroianni R; Piszczek R; Xylinas E; Zdrojowy R;
Arab J Urol; 2021 Jan; 19(1):78-85. PubMed ID: 33763252
[TBL] [Abstract][Full Text] [Related]
20. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
